QM · rank #8 · 2026-09-10
SNT
GPW · PLN · $778M (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +79.09% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +55.1% |
| Profit margin Net profit margin, trailing 12 months. | +16.1% |
| Market cap (USD) Size filter: > $300M required (USD-equivalent). | $778M |
| Anchor (recent) Close on 2026-08-11 | $366.20 |
| Anchor (far) Close on 2025-08-11 | $204.48 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik is Poland's dominant PET/CT radiopharmaceutical producer and diagnostic imaging integrator, operating three dedicated tracer plants and bundling isotope supply, hardware, and radiology IT for oncology centres across Poland and nascent CEE export markets.
Rationale
The 79% trailing momentum is grounded in verified fundamental acceleration — 52% revenue growth, 62% operating profit growth, and a 55% ROE — making this a quality-driven momentum signal rather than a sentiment-only rotation, which is precisely the edge quality_momentum seeks.
Material risks
- 1Hospital nuclear-medicine labs or competing producers expanding in-house PET tracer capacity in Poland would directly erode Synektik's bundled-supply moat, the structural bottleneck that justifies both the premium margin (16% net) and the quality screen.
- 2Revenue is heavily tender-dependent on Polish public hospitals and KPO/e-Zdrowie program disbursements, meaning a healthcare budget freeze or EU funding delay could abruptly flatten the growth trajectory that sustains the momentum signal — management has already flagged near-term result flattening.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.